Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: U3-1287|DRUG: Trastuzumab|DRUG: Paclitaxel|DRUG: U3-1287|DRUG: Trastuzumab|DRUG: Paclitaxel|DRUG: Placebo
Sponsor: Daiichi Sankyo